In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
Interested in acute cardiovascular care?

Watch webinars and videos, download presentations and read abstracts on ESC 365, the cardiology knowledge hub.

Access now

P2Y12-inhibitors in NSTEMI - old and new guidelines

Association for Acute CardioVascular Care webinar

16/02/2021 18:00 16/02/2021 19:00 Europe/Paris P2Y12-inhibitors in NSTEMI - old and new guidelines

Access event page

Association for Acute CardioVascular Care DD/MM/YYYY
Association for Acute CardioVascular Care
Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care

Focus on

Needs assessment:

The new ESC Clinical Practice Guidelines on NSTEMI recommend prasugrel over ticagrelor in ACS patients referred for percutaneous coronary intervention (PCI). At the same time, these guidelines recommend using prasugrel only after the coronary anatomy is known and avoiding pre-cath lab use of P2Y12 inhibitors. This changes clinical routine essentially:

  1. In many systems of ACS care, high-risk ACS patients cannot be treated by PCI within 24 hours of diagnosis and are, therefore, frequently pre-treated with ticagrelor or clopidogrel.
  2. Patients with ACS but without indication for PCI frequently receive ticagrelor as a conservative strategy.
  3. In ACS patients with high or very high bleeding risk and in patients without increased bleeding risk, clopidogrel and ticagrelor, respectively, have been tested for short DAPT (one to three months), followed by P2Y12 inhibitor monotherapy with significantly reduced bleeding hazards, but with similar ischaemic outcome. No data are currently available for the use of prasugrel in this strategy.


Learning objectives

After watching this webinar, participants will be able to:

• recognise the correct use of P2Y12 inhibitors (ticagrelor and prasugrel) in patients presenting with non-ST-elevation ACS;
• implement into practice the ‘2020 ESC Guidelines on Non-ST-Elevation ACS’; and
• manage new indications for ticagrelor in ACS patients, namely as monotherapy after short-duration DAPT.


Watch the webinar recording



Stefan James Photo2.jpgProfessor Stefan James
Uppsala University
Uppsala, Sweden

Kristensen-Steen-Dalby-2016.jpgProfessor Steen Dalby Kristensen
Aarhus University Hospital
Aarhus, Denmark


huber-kurt-2013.jpgProfessor Kurt Huber
Wilhelminen Hospital
Vienna, Austria


Session information

This webinar is designed for ACVC members but also cardiologists wishing to update their scientific knowledge on the topic.

During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.

An application has been made to the EACCME® for CME accreditation of this event.

Technical settings

The webinar is available on PC and tablets. The use of a smartphone is not recommended.

To answer the MCQs during the live, you must allow pop-up windows.

A high-speed Internet connection is required (minimum 2 Mbps).